Your session is about to expire
← Back to Search
CPI-613 + FOLFIRINOX for Locally Advanced Pancreatic Cancer
Study Summary
This trial is testing a new combination of drugs to treat pancreatic cancer that has not spread and is not able to be removed by surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My pancreatic cancer can be surgically removed.I have a serious illness that could make treatment more risky for me.I am not HIV-positive or not on antiretroviral therapy.My cancer is confirmed as pancreatic adenocarcinoma through testing.You are expected to live for less than 3 months.I have a specific type of pancreatic cancer.I have had surgery or medical treatment for pancreatic cancer.I do not have any uncontrolled illnesses that could interfere with the study.My pancreatic cancer is advanced but hasn't spread far, as confirmed by scans.I am very active or have minor symptoms that don't limit my daily activities.My blood, liver, kidney functions are normal, and I am expected to live at least 3 more months.I am using birth control and have a recent negative pregnancy test.I am a man who can father children and will use birth control during the study, unless I'm infertile.I haven't had a serious infection or been hospitalized for one in the last month.My pancreatic cancer has spread, as shown by scans.I am a man who can father children and will not use birth control during the study.I haven't received any cancer treatments aimed at extending my life in the last 2 weeks.I am not pregnant, breastfeeding, or if capable of becoming pregnant, I am using reliable contraception.I do not have any ongoing, uncontrolled bleeding issues.I had a heart attack less than 3 months ago.
- Group 1: Standard Dose Cohort: CPI-613 + mFOLFIRINOX
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research opportunity available to elderly individuals?
"This clinical investigation is open to patients aged 18-80. There are 83 studies available for minors and 1193 research projects dedicated to seniors."
What have clinical trials revealed about the efficacy of CPI 613?
"CPI 613 is typically administered to patients with colorectal carcinoma. Additionally, it has also been considered a viable treatment for ovarian cancer, sarcoma and metastatic colorectal carcinoma."
Are there any restrictions to participating in this medical trial?
"Candidates wishing to participate in this clinical trial must prove that they have malignant neoplasm of pancreas and fall within the age range of 18-80. The researchers are seeking 49 volunteers for their research."
What is the ultimate goal of this research endeavor?
"The primary endpoint of this trial, measured over a 4-week period from the outset of treatment, is Overall Survival. Secondary outcomes include Response rates per RECIST version 1.1 (complete response, partial response and stable disease), Surgical resection rate for those initially deemed borderline or non-resectable after receiving protocol treatments; and Resection margins with 95% confidence intervals estimated to measure the success rate of negative margin removal."
Could you provide details regarding the current status of recruitment for this trial?
"At this time, the clinical trial is not accepting participants. It was posted on December 7th 2018 and last updated on September 14th 2022. However, if you are seeking other studies, 697 trials for malignant neoplasm of pancreas and 558 studies for CPI 613 have openings in their enrolment process."
What previous research has been done using CPI 613?
"Presently, 558 trials are underway to investigate the effects of CPI 613. Out of these studies, 171 have progressed to Phase 3 and most clinical sites for this medication are located in Woolloongabba, Queensland with a total of 22492 locations running tests."
What is the current caseload of this clinical experiment?
"This research is no longer accepting participants. It was initially made public on December 7th 2018, and its most recent update occurred September 14th 2022. If you are looking for a different clinical trial, at present there are 697 trials actively enrolling individuals with malignant neoplasm of pancreas and 558 studies involving CPI613 that have open slots for interested parties."
Share this study with friends
Copy Link
Messenger